As­traZeneca’s Imfinzi aces Phase 3 test in blad­der can­cer, fails an­oth­er in lung can­cer

You win some, you lose some: As­traZeneca’s block­buster can­cer med­i­cine Imfinzi has suc­ceed­ed in a late-stage blad­der can­cer tri­al, but dis­ap­point­ed in a sep­a­rate Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.